FDA Clearance Tracker · P250021
saypha® ChiQ
Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jun 12, 2026
Approved
Time to decision
351 days
Received Jun 26, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P250021
- Device name
- saypha® ChiQ
- Applicant
- Croma-Pharma GmbH
- Applicant location
- Leobendorf
- Received
- Jun 26, 2025
- Decided
- Jun 12, 2026
- Decision
- Approved
- Supplements
- 2 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Implant, dermal, for aesthetic use (LMH)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
saypha® ChIQ is indicated for use in cheek augmentation and restoring midface volume deficits in patients over the age of 21. The device is indicated to be administered by subcutaneous and/or supraperiosteal injection.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code LMH. The earliest in FDA's data is P800022, decided Jul 22, 1981.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Croma-Pharma GmbH
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P240008 · Decided Sep 8, 2025 · 530 days after receipt
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.